EdwardSamuelCornwall/iStock via Getty Images
- SciSparc (NASDAQ:SPRC) said on Wednesday it completed the development of its drug candidate, SCI-110, for Phase IIb study to treat tourette syndrome.
- SCI-110 is developed and manufactured by Procaps Group S.A.
- Tourette syndrome is a movement and neurobehavioral disorder characterized by chronic motor and vocal tics.
- The main goal of the study is to assess tic severity change as a continuous endpoint at week 12 and week 26.